Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 3.9% – Time to Sell?

by · The Markets Daily

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report)’s stock price was down 3.9% during trading on Thursday . The stock traded as low as $37.51 and last traded at $37.51. Approximately 81,594 shares were traded during trading, a decline of 89% from the average daily volume of 719,378 shares. The stock had previously closed at $39.02.

Analyst Ratings Changes

AGIO has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday. Raymond James reissued an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Royal Bank of Canada raised their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Finally, Scotiabank raised their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $56.33.

View Our Latest Analysis on Agios Pharmaceuticals

Agios Pharmaceuticals Stock Down 1.1 %

The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 3.12 and a beta of 0.80. The firm has a 50 day moving average of $49.79 and a 200 day moving average of $46.65.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals during the second quarter valued at about $37,000. Quest Partners LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC raised its stake in shares of Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $146,000.

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

Read More